Immutep

Entering Phase I

image lmmutep Announces That ImmuFact IMP321 Has Entered a Phase I clinical trial in metastatic melanoma in a novel protocol combining adoptive T cell transfer after transient lymphodepletion associated with peptide vaccination

Published 09/2007 by admin@immutep.com
» Office and Laboratory Leases
© 2002 Immutep, S.A.
Press Release
06/2008 - LAG-3 Enhances Activity of a Cellular Cancer Immunotherapy
image Immutep S.A. announced today the publication of research conducted by ...
11/2007 - IMP321 first results in metastatic breast cancer
image Immutep S.A announced positive interim results from a Phase I/II ...
09/2007 - IMP321’s potency as a new immunopotentiator in cancer patients
image Immutep Announces That ImmuFact® IMP321 Induces Activation of a Wide ...
09/2007 - Entering Phase I
image lmmutep Announces That ImmuFact IMP321 Has Entered a Phase I ...
10/2006 - Entering Phase I
image lmmutep Announces That ImmuFact IMP321 Has Entered a Phase I ...